Switch theme
Sign up to access all valuation multiples
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Marker Therapeutics has a last 12-month revenue of $8.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Marker Therapeutics achieved revenue of n/a and an EBITDA of -$14.6M.
Marker Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Marker Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.5M | n/a | $9.6M | $8.5M | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$26.3M | -$14.6M | n/a | n/a | XXX |
| EBITDA Margin | -478% | -Infinity% | NaN% | 0% | XXX |
| Net Profit | -$41.9M | -$29.9M | -$8.2M | XXX | XXX |
| Net Margin | -761% | -Infinity% | -86% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Marker Therapeutics's stock price is $2.
Marker Therapeutics has current market cap of $16.8M, and EV of -$1.3M.
See Marker Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$1.3M | $16.8M | XXX | XXX | XXX | XXX | $-0.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Marker Therapeutics has market cap of $16.8M and EV of -$1.3M.
Marker Therapeutics's trades at -0.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Marker Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Marker Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$1.3M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -2.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMarker Therapeutics's NTM/LTM revenue growth is -78%
Marker Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.8M for the same period.
Over next 12 months, Marker Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Marker Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Marker Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marker Therapeutics acquired XXX companies to date.
Last acquisition by Marker Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Marker Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Marker Therapeutics founded? | Marker Therapeutics was founded in 1992. |
| Where is Marker Therapeutics headquartered? | Marker Therapeutics is headquartered in United States of America. |
| How many employees does Marker Therapeutics have? | As of today, Marker Therapeutics has 8 employees. |
| Who is the CEO of Marker Therapeutics? | Marker Therapeutics's CEO is Dr. Juan Vera, M.D.. |
| Is Marker Therapeutics publicy listed? | Yes, Marker Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Marker Therapeutics? | Marker Therapeutics trades under MRKR ticker. |
| When did Marker Therapeutics go public? | Marker Therapeutics went public in 1998. |
| Who are competitors of Marker Therapeutics? | Similar companies to Marker Therapeutics include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Marker Therapeutics? | Marker Therapeutics's current market cap is $16.8M |
| What is the current revenue of Marker Therapeutics? | Marker Therapeutics's last 12-month revenue is $8.5M. |
| What is the current EV/Revenue multiple of Marker Therapeutics? | Current revenue multiple of Marker Therapeutics is -0.2x. |
| Is Marker Therapeutics profitable? | Yes, Marker Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
